Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REAL-WORLD, LONG-TERM DATA COLLECTION TO GAIN CLINICAL INSIGHTS INTO ROCHE OPHTHALMOLOGY PRODUCTS
jRCT1031220434Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of faricimab in exudative macular degeneration, diabetic macular edema (DME), Vein occlusion (RVO) and 3 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change in visual acuity at 12 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)Vein occlusion (RVO)branch retinal vein occlusion (BRVO)central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on jRCT1031220434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220434.